Clinical Report: Can BioTAK Identify Broken Heart Syndrome?

Overview

The BioTAK score is a blood-based diagnostic tool developed using data from over 3,600 patients, utilizing four biomarkers and patient sex.

Background

Takotsubo syndrome, or broken heart syndrome, mimics acute coronary syndrome, complicating timely diagnosis and treatment. Accurate differentiation is crucial.

Data Highlights

Key Findings

• BioTAK score uses four biomarkers: NT-proBNP, LDL cholesterol, sLOX-1, and PAM.
• Patients with takotsubo syndrome had higher levels of NT-proBNP and PAM.
• Patients with acute coronary syndrome had higher levels of sLOX-1 and LDL cholesterol.
• BioTAK achieved an AUC of 0.97 in the development cohort and 0.93 in the validation cohort.
• A score below 27 indicates a 95.7% sensitivity for ruling out takotsubo syndrome.
• A score of 33 or higher indicates 99% specificity, but a positive predictive value of only 59.1%.

Clinical Implications

The BioTAK score is not intended to replace urgent coronary angiography in high-risk patients.

Conclusion

Further validation and assay development are necessary for routine clinical use.

Related Resources & Content

1. Wenzl F, et al., European Heart Journal, 2026 -- Takotsubo syndrome diagnosis: the biomarker-based BioTAK score
2. Clinical Research in Cardiology — Mechanical circulatory support for cardiogenic shock in takotsubo syndrome
3. the pathologist — Heart of the Matter
4. Clinical Research in Cardiology — Correction to: The Diagnostic Significance of Specific Cardiovascular Biomarkers in Takotsubo Syndrome
5. Comparison of troponin and natriuretic peptides in Takotsubo syndrome and acute coronary syndrome: a meta-analysis - PubMed
6. MDSpire News — Men With Broken Heart Syndrome Have Twice the Mortality Risk: Study
7. Takotsubo syndrome diagnosis: the biomarker-based BioTAK score | European Heart Journal | Oxford Academic
8. Comparison of troponin and natriuretic peptides in Takotsubo syndrome and acute coronary syndrome: a meta-analysis - PubMed